

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/597,521	
				FILING DATE			
				APPLICANT		Eatherton et al.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PB60754USW	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,112,820	5/12/1992	Ward et al.			
	2	5,925,768	7/20/1999	Sanofi et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	3	EP 0569912	11/18/1993	EUROPE			X Abstract
	4	EP 0576357	12/29/1993	EUROPE			X Abstract
	5	FR 2839718	11/21/2003	FRANCE			X Abstract
	6	WO 02/04429	1/17/2002	WIPO			
	7	WO 02/060447	8/8/2002	WIPO			
	8	WO 02/062750	8/15/2002	WIPO			
	9	WO 02/66036	8/29/2002	WIPO			
	10	WO 04/00807	12/31/2003	WIPO			
	11	WO 04/002964	8/1/2004	WIPO			X Abstract
	12	WO 04/018433	3/4/2004	WIPO			
	13	WO 04/029026	4/8/2004	WIPO			
	14	WO 04/029027	4/8/2004	WIPO			
	15	WO 04/029204	4/8/2004	WIPO			
	16	WO 04/085385	10/7/2004	WIPO			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	17	Huffman, J.W. "The Search For Selective Ligands For The CB2 Receptor." Currently Pharmaceutical Design, Bentham Science Publishers, Vol. 6, No. 13. 2000, pgs. 1323-1337.					
	18	Souness, J.E. "Immunosuppressive And Anti-inflammatory Effect of Cyclic AMP." Immunopharmacology, 2000. 47/2-3; 127-162					
	19	Huang, Z., et al. "Next Generation of PDE4 Inhibitors." Current Opinion in Chemical Biology, 2001, pgs. 432-438.					
	20	Sullivan, R.W., et al. "2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'-bis(trifluoromethyl)phenyl)-carboxamide Potent Inhibitor of NF-KB-and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry; J. Med. Chem.; 1998; 41; 413-419.					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							